Introduction Nitrosamine limits apply both to individual impurities and to their cumulative total whenever two or more N-nitrosamines are detected […]
Introduction: A virtual biotech can reach IND clearance in about 9 months when its CMC (Chemistry, Manufacturing and Controls) strategy
Introduction Qualifying active pharmaceutical ingredient (API) vendors and contract manufacturing organizations (CMOs) requires Nitrosamine Risk Assessment Services for API Suppliers
Introduction Nitrosamine Testing for Peptide and GLP-1 drug products requires a comprehensive evaluation of synthetic-route risks, peptide-specific sample preparation, and
Nitrosamine Testing for Peptide and GLP-1 Drug Products: Specialized CRO Services Read More »
Introduction Selecting a qualified Nitrosamine Testing Laboratory in Canada requires verification of active Drug Establishment Licence (DEL) compliance, highly sensitive
Introduction Forced Degradation Studies in CMC serve as the mechanistic engine of a defensible pharmaceutical impurity control strategy, linking intrinsic
Forced Degradation Studies in CMC: Building a Robust Impurity Control Strategy Read More »
Introduction Under the harmonized ICH M10 guideline, which was adopted at Step 4 on May 24, 2022, issued by the
Introduction Effective Calibration Curve Design and Regression Weighting in LC-MS/MS bioanalysis requires matching the mathematical order of the calibration function
Introduction: Polymorphism solid-state characterization CMC work answers one regulatory question: is the crystal form of your drug substance known, stable
Introduction: The ICH Q11 CMC drug development guidelines, read together with ICH Q8(R2), explain how sponsors should design, justify and
ICH Q11 and Q8 Guidelines in CMC Drug Development: A Practical Overview for Sponsors Read More »
